Eli Lilly Stock a Buy After FDA Signs Off on New Weight-Loss Drug? Hosted by Laycee KluinNovember 28, 2023 ShareLink copied to clipboard. Play video for Eli Lilly Stock a Buy After FDA Signs Off on New Weight-Loss Drug?DetailsGuestsIn this video, we dive into the evolving pharmaceutical landscape with Dylan Jovine from Behind the Markets. We unpack the explosive growth expected in the weight loss drug industry, projected to hit a whopping $150-200 billion by 2030. There are major players strategically positioning themselves in this market, and we'll uncover the intense competition between giants like Novo Nordisk and Eli Lilly, fighting for dominance with their groundbreaking weight loss drugs. Plus, discover the potential impact on stock values and the healthcare industry as a whole. We'll also discuss the critical phase transitions in FDA drug approval, spotting opportunities, and why investing in biotech has Dylan so bullish on its future.Read Ozempic vs. Mounjaro:: Battle of the bulgeStocks Mentioned in This EpisodeCompanyMarketRank™Current PriceDividend YieldP/E RatioLLYEli Lilly and Company4.9972 of 5 stars$754.90-0.2%0.79%49.34NVONovo Nordisk A/S4.0921 of 5 stars$54.94+1.2%1.49%15.09 Compare These Stocks Add These Stocks to My Watchlist Laycee Kluin, HostDigital Marketing Strategist, MarketBeatAs MarketBeat's Digital Marketing Strategist, Laycee helps with the marketing side of tasks including developing email campaigns, running the promotion of the MarketBeat products and exploring social media opportunities. She felt called to the Marketing industry because she enjoys collaborating with people and making connections. The University of Sioux Falls alum majored in Media Studies with minors in Communications and Spanish. Laycee brings a background in Financial Services Marketing.Previous VideoAll VideosNext Video Subscribe on YouTube Don't Miss a Video Subscribe to watch the latest stock market videos from MarketBeat. We empower investors to make better trading decisions by providing real-time financial data and objective market analysis. Subscribe on YouTube From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredApple’s falling behindApple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors o...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Listen to MarketBeat Other Platforms September 2, 2025Markets Are Sliding: Where to Find OpportunityMarkets are starting September with a pullback, and our guests from the New Money Crew — Nate Tucci and Graham Lindman — are here to break it all down.Watch VideoRelated Videos Featured Articles and Offers2 Data Center REITs That Look Good in Any PortfolioSeptember 8, 2025REVEALED FREE: Our top 3 stocks to own in 2025 and beyondFrom Weiss Ratings (Ad)What NVIDIA’s Big Bet on Rival Quantinuum Means for D-Wave StockSeptember 8, 2025Eyes on the Sky: AST SpaceMobile Prepares for Commercial LaunchSeptember 8, 2025Intel's Silent Comeback: 3 Pillars the Market Is OverlookingSeptember 12, 2025Retire Comfortably with These New Monthly Income ETFs?From Investors Alley (Ad) Search Headlines Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Hosted by Laycee KluinNovember 28, 2023 ShareLink copied to clipboard. Play video for Eli Lilly Stock a Buy After FDA Signs Off on New Weight-Loss Drug?DetailsGuestsIn this video, we dive into the evolving pharmaceutical landscape with Dylan Jovine from Behind the Markets. We unpack the explosive growth expected in the weight loss drug industry, projected to hit a whopping $150-200 billion by 2030. There are major players strategically positioning themselves in this market, and we'll uncover the intense competition between giants like Novo Nordisk and Eli Lilly, fighting for dominance with their groundbreaking weight loss drugs. Plus, discover the potential impact on stock values and the healthcare industry as a whole. We'll also discuss the critical phase transitions in FDA drug approval, spotting opportunities, and why investing in biotech has Dylan so bullish on its future.Read Ozempic vs. Mounjaro:: Battle of the bulgeStocks Mentioned in This EpisodeCompanyMarketRank™Current PriceDividend YieldP/E RatioLLYEli Lilly and Company4.9972 of 5 stars$754.90-0.2%0.79%49.34NVONovo Nordisk A/S4.0921 of 5 stars$54.94+1.2%1.49%15.09 Compare These Stocks Add These Stocks to My Watchlist Laycee Kluin, HostDigital Marketing Strategist, MarketBeatAs MarketBeat's Digital Marketing Strategist, Laycee helps with the marketing side of tasks including developing email campaigns, running the promotion of the MarketBeat products and exploring social media opportunities. She felt called to the Marketing industry because she enjoys collaborating with people and making connections. The University of Sioux Falls alum majored in Media Studies with minors in Communications and Spanish. Laycee brings a background in Financial Services Marketing.Previous VideoAll VideosNext Video Subscribe on YouTube Don't Miss a Video Subscribe to watch the latest stock market videos from MarketBeat. We empower investors to make better trading decisions by providing real-time financial data and objective market analysis. Subscribe on YouTube From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredApple’s falling behindApple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors o...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored
